TransThera Sciences - Public Comps and Valuation Multiples

TransThera Sciences Overview

About TransThera Sciences

TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.

Founded

2014

HQ

Employees

121

Website

transthera.com

Sectors

Drug Development & Therapeutics

Financials

Last FY Revenue n/a

Last FY EBITDA -$34.4M

EV

$10.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

TransThera Sciences Financials

See TransThera Sciences valuation multiples based on analyst estimates

TransThera Sciences P&L

In the most recent fiscal year, TransThera Sciences reported EBITDA of -$34.4M.

TransThera Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

See TransThera Sciences valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	n/a	XXX	XXX	XXX
Gross Profit	XXX	n/a	XXX	XXX	XXX
Gross Margin	XXX	n/a	XXX	XXX	XXX
EBITDA	XXX	-$34.4M	XXX	XXX	XXX
EBITDA Margin	XXX	n/a	XXX	XXX	XXX
EBIT	XXX	-$34.6M	XXX	XXX	XXX
EBIT Margin	XXX	n/a	XXX	XXX	XXX
Net Profit	XXX	-$35.2M	XXX	XXX	XXX
Net Margin	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for TransThera Sciences including revenue, profitability, and margin analysis across different time periods.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$34.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$34.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$35.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for TransThera Sciences

This financial data table provides comprehensive performance metrics for TransThera Sciences, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

Fiscal year EBITDA was -$34.4M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for TransThera Sciences. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

TransThera Sciences Stock Performance

TransThera Sciences has current market cap of HKD 83.0B (or $10.6B), and EV of HKD 82.3B (or $10.6B).

Market Cap Evolution

TransThera Sciences Stock Data

As of September 17, 2025, TransThera Sciences's stock price is HKD 209 (or $27).

See TransThera Sciences trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$10.6B	$10.6B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

TransThera Sciences Valuation Multiples

TransThera Sciences's trades at 69720.1x EV/Revenue multiple, and -307.3x EV/EBITDA.

See valuation multiples for TransThera Sciences and 15K+ public comps

TransThera Sciences Financial Valuation Multiples

As of September 17, 2025, TransThera Sciences has market cap of $10.6B and EV of $10.6B.

Equity research analysts estimate TransThera Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

TransThera Sciences's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$10.6B	XXX	$10.6B	XXX	XXX	XXX
EV (current)	$10.6B	XXX	$10.6B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	69720.1x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-307.3x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-305.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-302.4x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-302.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TransThera Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

TransThera Sciences Margins & Growth Rates

TransThera Sciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.3M for the same period.

TransThera Sciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TransThera Sciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for TransThera Sciences and other 15K+ public comps

TransThera Sciences Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial